Abstract

Over 350 millions of people suffer from depression worldwide, and an increase in the incidence of the disease is expected in the coming years. Therefore, there is a strong need of knowing the mechanisms of development this disease and its effective treatment. Pharmacological therapy is an essential element of antidepressant therapy and its failure is a serious problem in clinical psychiatry. In spite of large number of available medicines, only 50% of patients achieved remission after single-drug treatment. Genetic factors which predispose to depression development and predict an outcome of its pharmacotherapy, probably play a substantial role in these phenomena. In spite of this, they are still not characterized enough and applied in practice. Therefore, the aim of this study is to present the current knowledge of the impact of selected genes on pharmacokinetics and pharmacodynamics of antidepressants by changing function and/or structure of encoded proteins. In the review the best known polymorphisms of selected genes encoding isoenzymes of cytochrome P-450, responsible for metabolism of popular antidepressant drugs, namely CYP2C19, CYP2D6, CYP1A2, and CYP3A4/5 are described. Further, 4 polymorphisms of ABCB1 gene (rs 1045642, rs 2032582, rs 1128503 and rs 2032583) encoding glycoprotein P, which play a key role in transportation of large number of drugs used in treatment of depression. For benefit of treatment of patients with depression, it is worthy to estimate and to take on the board all so far known mechanisms of planning therapy.

References

• 1. Bamburowicz-Klimkowska M., Bogucka U., Szutowski M.M.: Funkcjetransporterów typu ABC. Biul. Wydz. Farm. WUM, 2011; 3: 34-40
  Google Scholar
• 2. Bertilsson L.: Metabolism of antidepressant and neuroleptic drugsby cytochrome p450s: clinical and interethnic aspects. Clin. Pharmacol.Ther., 2007; 82: 606-609
  Google Scholar
• 3. Brachtendorf L., Jetter A., Beckurts K.T., Hölscher A.H., Fuhr U.:Cytochrome P450 enzymes contributing to demethylation of maprotilinein man. Pharmacol. Toxicol., 2002; 90: 144-149
  Google Scholar
• 4. Ejsing T.B., Linnet K.: Influence of P-glycoprotein inhibition onthe distribution of the tricyclic antidepressant nortriptyline overthe blood-brain barrier. Hum. Psychopharmacol., 2005; 20: 149-153
  Google Scholar
• 5. Fujii T., Ota M., Hori H., Sasayama D., Hattori K., Teraishi T., YamamotoN., Hashikura M., Tatsumi M., Higuchi T., Kunugi H.: Associationbetween the functional polymorphism (C3435T) of the gene encodingP-glycoprotein (ABCB1) and major depressive disorder in theJapanese population. J. Psychiatr. Res., 2012; 46: 555-559
  Google Scholar
• 6. Fukui N., Suzuki Y., Sawamura K., Sugai T., Watanabe J., InoueY., Someya T.: Dose-dependent effects of the 3435 C>T genotype ofABCB1 gene on the steady-state plasma concentration of fluvoxaminein psychiatric patients. Ther. Drug Monit., 2007; 29: 185-189
  Google Scholar
• 7. Fung K.L., Gottesman M.M.: A synonymous polymorphism ina common MDR1 (ABCB1) haplotype shapes protein function. Biochim.Biophys. Acta, 2009; 1794: 860-871
  Google Scholar
• 8. Gervasini G., Carrillo J.A., Garcia M., San Jose C., Cabanillas A., BenitezJ.: Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrugresistance 1) G2677T/A gene polymorphism is associated withhigh risk of lung cancer. Cancer, 2006; 107: 2850-2857
  Google Scholar
• 9. Grandjean-Forestier F., Stenger C., Robert J., Verdier M., RatinaudM.H.: The P-glycoprotein 170: Just a multidrug resistance protein ora protean molecule? W: ABC transporters and multidrug resistance,A. Boumendjel, J. Boutonnat, J. Robert. John Wiley & Sons, Inc.,New Jersey 2009, 18-46
  Google Scholar
• 10. Hiemke C., Härtter S.: Pharmacokinetics of selective serotoninreuptake inhibitors. Pharmacol. Ther., 2000; 85: 11-28
  Google Scholar
• 11. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmöller J.,Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., BrinkmannU.: Functional polymorphisms of the human multidrug-resistancegene: multiple sequence variations and correlation of one allele withP-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci.USA, 2000; 97: 3473-3478
  Google Scholar
• 12. Horinouchi M., Sakaeda T., Nakamura T., Morita Y., TamuraT., Aoyama N., Kasuga M., Okumura K.: Significant genetic linkageof MDR1 polymorphisms at positions 3435 and 2677: functionalrelevance to pharmacokinetics of digoxin. Pharm. Res., 2002; 19:1581-1585
  Google Scholar
• 13. Horstmann S., Binder E.B.: Pharmacogenomics of antidepressantdrugs. Pharmacol. Ther., 2009; 124: 57-73
  Google Scholar
• 14. Huff L.M., Lee J.S., Robey R.W., Fojo T.: Characterization of generearrangements leading to activation of MDR-1. J. Biol. Chem., 2006;281: 36501-36509
  Google Scholar
• 15. Ingelman-Sundberg M.: Genetic polymorphisms of cytochromeP450 2D6 (CYP2D6): clinical consequences, evolutionary aspects andfunctional diversity. Pharmacogenomics J., 2005; 5: 6-13
  Google Scholar
• 16. Ingelman-Sundberg M., Sim S.C., Gomez A., Rodriguez-AntonaC.: Influence of cytochrome P450 polymorphisms on drug therapies:pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol.Ther., 2007; 116: 496-526 17 Jamroziak K., Balcerczak E., Młynarski W., Mirowski M., Robak T.:Distribution of allelic variants of functional C3435T polymorphismof drug transporter MDR1 gene in a sample of Polish population.Pol. J. Pharmacol., 2002; 54: 495-500
  Google Scholar
• 17. allele on serum concentration ofescitalopram in psychiatric patients. Clin. Pharmacol. Ther., 2008;83: 322-327
  Google Scholar
• 18. Jamroziak K., Robak T.: Wpływ polimorfizmu genu MDR1 na zachorowalnośći przebieg kliniczny nowotworów układu krwiotwórczego.Acta Haematol. Pol., 2004; 35: 157-175
  Google Scholar
• 19. Jensen B.P., Roberts R.L., Vyas R., Bonke G., Jardine D.L., BeggE.J.: Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptylinepharmacokinetics and nortriptyline-induced postural hypotensionin healthy volunteers. Br. J. Clin. Pharmacol., 2012; 73: 619-628
  Google Scholar
• 20. Kastelic M., Koprivsek J., Plesnicar B.K., Serretti A., Mandelli L.,Locatelli I., Grabnar I., Dolzan V.: MDR1 gene polymorphisms andresponse to acute risperidone treatment. Prog. Neuropsychopharmacol.Biol. Psychiatry, 2010; 34: 387-392
  Google Scholar
• 21. Kato M., Fukuda T., Serretti A., Wakeno M., Okugawa G., IkenagaY., Hosoi Y., Takekita Y., Mandelli L., Azuma J., Kinoshita T.: ABCB1(MDR1) gene polymorphisms are associated with the clinical responseto paroxetine in patients with major depressive disorder.Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008; 32: 398-404
  Google Scholar
• 22. Keers R., Aitchison K.J.: Pharmacogenetics of antidepressantresponse. Expert Rev. Neurother., 2011; 11: 101-125
  Google Scholar
• 23. Kimchi-Sarfaty C., Oh J.M., Kim I.W., Sauna Z.E., Calcagno A.M.,Ambudkar S.V., Gottesman M.M.: A “silent” polymorphism in theMDR1 gene changes substrate specificity. Science, 2007; 315: 525-528
  Google Scholar
• 24. Komar A.A.: Silent SNPs: impact on gene function and phenotype.Pharmacogenomics, 2007; 8: 1075-1080
  Google Scholar
• 25. Kopka M., Kotowicz J.: Zespół DEC (depresja, zaburzenia erekcji,choroba niedokrwienna serca) – niedodiagnozowana triada. PolskiPrzegląd Medycyny Lotniczej, 2008; 3: 269-276
  Google Scholar
• 26. Kurzawski M., Gawrońska-Szklarz B., Wrześniewska J., Siuda A.,Starzyńska T., Droździk M.: Effect of CYP2C19 17 gene variant onHelicobacter pylori eradication in peptic ulcer patients. Eur. J. Clin.Pharmacol., 2006; 62: 877-880
  Google Scholar
• 27. Laika B., Leucht S., Steimer W.: ABCB1 (P-glycoprotein/MDR1)gene G2677T/a sequence variation (polymorphism): lack of associationwith side effects and therapeutic response in depressed inpatientstreated with amitriptyline. Clin. Chem., 2006; 52: 893-895
  Google Scholar
• 28. Lessard E., Yessine M.A., Hamelin B.A., O’Hara G., LeBlanc J., TurgeonJ.: Influence of CYP2D6 activity on the disposition and cardiovasculartoxicity of the antidepressant agent venlafaxine in humans.Pharmacogenetics, 1999; 9: 435-443
  Google Scholar
• 29. Lin K.M., Tsou H.H., Tsai I.J., Hsiao M.C., Hsiao C.F., Liu C.Y., ShenW.W., Tang H.S., Fang C.K., Wu C.S., Lu S.C., Kuo H.W., Liu S.C., ChanH.W., Hsu Y.T. i wsp.: CYP1A2 genetic polymorphisms are associatedwith treatment response to the antidepressant paroxetine. Pharmacogenomics,2010; 11: 1535-1543
  Google Scholar
• 30. Maines L.W., Antonetti D.A., Wolpert E.B., Smith C.D.: Evaluationof the role of P-glycoprotein in the uptake of paroxetine, clozapine,phenytoin and carbamazapine by bovine retinal endothelial cells.Neuropharmacology, 2005; 49: 610-617
  Google Scholar
• 31. Menu P., Gressier F., Verstuyft C., Hardy P., Becquemont L., CorrubleE.: Antidepressants and ABCB1 gene C3435T functional polymorphism:a naturalistic study. Neuropsychobiology, 2010; 62: 193-197
  Google Scholar
• 32. Nemeroff C.B., Owens M.J.: Treatment of mood disorders. Nat.Neurosci., 2002; 5 (Suppl. 1): 1068-1070
  Google Scholar
• 33. Nikisch G., Eap C.B., Baumann P.: Citalopram enantiomers in plasmaand cerebrospinal fluid of ABCB1 genotyped depressive patientsand clinical response: a pilot study. Pharmacol. Res., 2008; 58: 344-347
  Google Scholar
• 34. Panczyk M., Balcerczak E., Piaskowski S., Jamroziak K., Pasz-WalczakG., Mirowski M.: ABCB1 gene polymorphisms and haplotypeanalysis in colorectal cancer. Int. J. Colorectal Dis., 2009; 24: 895-905
  Google Scholar
• 35. Panczyk M., Sałagacka A., Mirowski M.: MDR1 (ABCB1) geneencoding glycoprotein P (P-gp), a member of ABC transporter superfamily:consequences for therapy and progression of neoplasticdiseases. Postępy Biochem., 2007; 53: 361-373
  Google Scholar
• 36. Pużyński S.: Leki przeciwdepresyjne oraz inne metody terapiibiologicznej. W: Depresje i zaburzenia afektywne, Pużyński S. (red.).Wydawnictwo Lekarskie PZWL, Warszawa 2009, 147-208
  Google Scholar
• 37. Roberts R.L., Joyce P.R., Mulder R.T., Begg E.J., Kennedy M.A.:A common P-glycoprotein polymorphism is associated with nortriptyline-inducedpostural hypotension in patients treated for majordepression. Pharmacogenomics J., 2002; 2: 191-196
  Google Scholar
• 38. Rudberg I., Mohebi B., Hermann M., Refsum H., Molden E.: Impactof the ultrarapid CYP2C19
  Google Scholar
• 39. Sakurai A., Onishi Y., Hirano H., Seigneuret M., Obanayama K.,Kim G., Liew E.L., Sakaeda T., Yoshiura K., Niikawa N., Sakurai M.,Ishikawa T.: Quantitative structure-activity relationship analysis andmolecular dynamics simulation to functionally validate nonsynonymouspolymorphisms of human ABC transporter ABCB1 (P-glycoprotein/MDR1).Biochemistry, 2007; 46: 7678-7693
  Google Scholar
• 40. Sarginson J.E., Lazzeroni L.C., Ryan H.S., Ershoff B.D., SchatzbergA.F., Murphy G.M.Jr.: ABCB1 (MDR1) polymorphisms and antidepressantresponse in geriatric depression. Pharmacogenet. Genomics,2010; 20: 467-475
  Google Scholar
• 41. Sauna Z.E., Kimchi-Sarfaty C., Ambudkar S.V., Gottesman M.M.:Silent polymorphisms speak: how they affect pharmacogenomicsand the treatment of cancer. Cancer Res., 2007; 67: 9609-9612
  Google Scholar
• 42. Sayyah M., Kamgarpour F., Maleki M., Karimipoor M., GharagozliK., Shamshiri A.R.: Association analysis of intractable epilepsywith C3435T and G2677T/A ABCB1 gene polymorphisms in Iranianpatients. Epileptic Disord., 2011; 13: 155-165
  Google Scholar
• 43. Schuetz E.G., Furuya K.N., Schuetz J.D.: Interindividual variationin expression of P-glycoprotein in normal human liver and secondaryhepatic neoplasms. J. Pharmacol. Exp. Ther., 1995; 275: 1011-1018
  Google Scholar
• 44. Siegsmund M., Brinkmann U., Scháffeler E., Weirich G., SchwabM., Eichelbaum M., Fritz P., Burk O., Decker J., Alken P., RothenpielerU., Kerb R., Hoffmeyer S., Brauch H.: Association of the P-glycoproteintransporter MDR1C3435T polymorphism with the susceptibilityto renal epithelial tumors. J. Am. Soc. Nephrol., 2002; 13: 1847-1854
  Google Scholar
• 45. Singh A.B., Bousman C.A., Ng C.H., Byron K., Berk M.: ABCB1polymorphism predicts escitalopram dose needed for remission inmajor depression. Transl. Psychiatry, 2012; 2: e198
  Google Scholar
• 46. Steimer W., Zöpf K., von Amelunxen S., Pfeiffer H., Bachofer J.,Popp J., Messner B., Kissling W., Leucht S.: Amitriptyline or not, thatis the question: pharmacogenetic testing of CYP2D6 and CYP2C19identifies patients with low or high risk for side effects in amitriptylinetherapy. Clin. Chem., 2005; 51: 376-385
  Google Scholar
• 47. Tang K., Ngoi S.M., Gwee P.C., Chua J.M., Lee E.J., Chong S.S., LeeC.G.: Distinct haplotype profiles and strong linkage disequilibriumat the MDR1 multidrug transporter gene locus in three ethnic Asianpopulations. Pharmacogenetics, 2002; 12: 437-450
  Google Scholar
• 48. Timucin M., Alagozlu H., Ozdemir S., Ozdemir O.: Associationbetween ABCB1 (MDR1) gene polymorphism and unresponsivenesscombined therapy in chronic hepatitis C virus. Hepat. Mon.,2013; 13: e7522
  Google Scholar
• 49. Uhr M., Grauer M.T.: abcb1ab P-glycoprotein is involved in theuptake of citalopram and trimipramine into the brain of mice. J.Psychiatr. Res., 2003; 37: 179-185
  Google Scholar
• 50. Uhr M., Grauer M.T., Holsboer F.: Differential enhancement of antidepressantpenetration into the brain in mice with abcb1ab (mdr1ab)P-glycoprotein gene disruption. Biol. Psychiatry, 2003; 54: 840-846
  Google Scholar
• 51. Uhr M., Steckler T., Yassouridis A., Holsboer F.: Penetration ofamitriptyline, but not of fluoxetine, into brain is enhanced in micewith blood-brain barrier deficiency due to mdr1a P-glycoproteingene disruption. Neuropsychopharmacology, 2000; 22: 380-387
  Google Scholar
• 52. Uhr M., Tontsch A., Namendorf C., Ripke S., Lucae S., Ising M.,Dose T., Ebinger M., Rosenhagen M., Kohli M., Kloiber S., SalyakinaD., Bettecken T., Specht M., Pütz B. i wsp.: Polymorphisms in the drugtransporter gene ABCB1 predict antidepressant treatment responsein depression. Neuron, 2008; 57: 203-209
  Google Scholar
• 53. Veefkind A.H., Haffmans P.M., Hoencamp E.: Venlafaxine serumlevels and CYP2D6 genotype. Ther. Drug Monit., 2000; 22: 202-208
  Google Scholar
• 54. Wienkers L.C., Allievi C., Hauer M.J., Wynalda M.A.: CytochromeP-450-mediated metabolism of the individual enantiomers of theantidepressant agent reboxetine in human liver microsomes. DrugMetab. Dispos., 1999; 27: 1334-1340
  Google Scholar
• 55. Wojtczak A., Skrętkowicz J.: Kliniczne znaczenie polimorfizmuwybranych genów cytochromu P-450: rodziny CYP1, podrodzinyCYP2A, CYP2B oraz CYP2C. Pol. Merkur. Lekarski, 2009; 26: 248-252
  Google Scholar
• 56. World Federation for Mental Health: Depression: a global crisis.http://wfmh.com/wp-content/uploads/2013/11/2012_wmhday_english.pdf(18.05.2015)
  Google Scholar
• 57. Yu K.S., Yim D.S., Cho J.Y., Park S.S., Park J.Y., Lee K.H., Jang I.J.,Yi S.Y., Bae K.S., Shin S.G.: Effect of omeprazole on the pharmacokineticsof moclobemide according to the genetic polymorphism ofCYP2C19. Clin. Pharmacol. Ther., 2001; 69: 266-273
  Google Scholar

Full text